Roche chief executive Thomas Schinecker said today that one in five of the pharma division’s pipeline of new molecular entities (NMEs) has been culled in the last few months as part of a shift ...

The U.S. FDA approved 16 drugs in February, up from 12 in January but still falling short of the 2024 monthly average of 19 approvals. Just two of those were new molecular entities (NMEs), continuing ...

MAXONA Pharmaceuticals today announced the preliminary results of the Phase 1 clinical program for MAX-001, which is in development as a New Molecular Entity (NME), non-opioid, non-NSAID oral therapy ...

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from its ...

First, clinical experience strongly indicates that some iron-overload diseases are unexplained despite an extensive molecular search and, therefore, that some new entities remain to be discovered.